BOSTON, Massachusetts — February 11, 2026 — Leads & Copy — Bioxytran, Inc. (OTCQB: BIXT) has announced positive clinical results from its Phase 2 trial evaluating ProLectin-M in subjects with laboratory-confirmed acute viral infection.
The Bioxytran Trial reports a complete elimination of viral load in 100% of patients at day 7 versus placebo (p=.001).
The Phase 2 clinical study was a randomized, double-blind, placebo-controlled, dose-optimization trial evaluating orally administered ProLectin-M in subjects with acute viral infection. The study enrolled 38 subjects, all of whom completed the study. Subjects were randomized to receive one of three ProLectin-M dose levels or a matching placebo, administered over a seven-day treatment period.
Viral shedding was assessed using RT-PCR analysis of nasopharyngeal swabs collected at predefined timepoints, with viral clearance defined as non-detection of viral RNA below established PCR thresholds.
The study design, endpoints, and duration confirmed Bioxytran’s earlier randomized, placebo-controlled Phase 2 trial, which demonstrated statistically significant reductions in viral load by Day 7, early clearance as soon as Day 3, and no observed viral rebounds during a 14-day post-treatment observation period. The current trial further refined dose selection of four tablets per day and evaluated the reproducibility of rapid viral clearance using the same core virologic assessment methodology.
Following database lock and unblinding, treatment-wise analyses demonstrated complete elimination of viral load in 100% of treated subjects by Day 7, compared to the placebo group (p = .001), and no viral rebounds observed in the treated population during the 14-day post-treatment observation period.
The company reports these results indicate rapid and sustained viral clearance in subjects treated with ProLectin-M.
Across the full study population:
Day 3: 1 of 38 subjects demonstrated non-detection of viral shedding.
Day 5: 16 of 38 subjects demonstrated non-detection of viral shedding.
Day 7: 38 of 38 subjects demonstrated non-detection of viral shedding.
The study was designed to evaluate viral clearance kinetics and inform dose selection for future late-stage clinical development.
Dr. Leslie Ajayi, Chief Medical Officer of Bioxytran, said the study design of seven days reflects real-world applications for treating acute viral diseases, with the objective of demonstrating a statistically meaningful reduction in viral load by Day 7. Ajayi added that the results demonstrate that viral clearance occurred more rapidly than anticipated, with a significant proportion of treated subjects achieving viral non-detection by Day 3 and complete clearance by Day 7.
Dr. Platt stated that what continues to distinguish ProLectin-M as a broad-range antiviral drug is its novel mechanism of action. Platt continued that rather than targeting viral replication inside the cell, the galectin antagonist is designed to interfere with viral entry at the cell surface, and this extracellular approach may reduce reliance on immune activation and represents a fundamentally different strategy in antiviral therapy. Platt also noted the belief that these results further support the potential of carbohydrate-based therapeutics and the emerging field of Glycovirology.
Based on these results, Bioxytran plans to advance regulatory discussions to support late-stage clinical development and evaluate ProLectin-M across additional viral indications consistent with its broad-spectrum antiviral profile.
Bioxytran, Inc. is a clinical-stage biotechnology company developing novel carbohydrate-based therapeutics targeting significant unmet medical needs in virology and other disease areas. The Company’s lead program, ProLectin-M, is being developed as a potential broad-spectrum antiviral therapeutic.
Source: Bioxytran, Inc.
